Rheumatoid Arthritis (RA) is a chronic autoimmune disease characterized by synovial inflammation and joint destruction. Treatment has progressed from broad immunosuppression to targeted therapy:
- TNF inhibitors (adalimumab, etanercept)
- IL-6 inhibitors (tocilizumab, sarilumab)
- JAK inhibitors (upadacitinib, baricitinib, tofacitinib)
Early aggressive treatment guided by treat-to-target strategies has significantly reduced disability.